A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K

Neuro-Oncology

Volumn 17, Issue 9, 2015, Pages 1261-1269

  Ma, Daniel J ^a   Galanis, Evanthia ^a   Anderson, S Keith ^a   Schiff, David ^b   Kaufmann, Timothy J ^a   Peller, Patrick J ^a   Giannini, Caterina ^a   Brown, Paul D ^a,c   Uhm, Joon H ^a   McGraw, Steven ^d   Jaeckle, Kurt A ^e   Flynn, Patrick J ^f   Ligon, Keith L ^g,h   Buckner, Jan C ^a   Sarkaria, Jann N ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Sioux Community Cancer Consortium   (United States)

^e MAYO CLINIC   (United States)

^f Metro Minnesota Community Oncology Research Consortium   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

everolimus; FLT PET; glioblastoma; mTOR

Indexed keywords

3' FLUOROTHYMIDINE F 18; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXON; FATIGUE; FOCUSED EXON SEQUENCING; GENE SEQUENCE; GLIOBLASTOMA; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SEPSIS; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIAGNOSTIC IMAGING; METABOLISM; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DACARBAZINE; DRUG THERAPY, COMBINATION; EVEROLIMUS; GLIOBLASTOMA; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84940748380     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou328     Document Type: Article

References (50)

1. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15(7):807-826.
2. Abraham RT. mTOR as a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol. 2004;279:299-319.
3. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110(2):163-175.
4. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14(14): 1296-1302.
5. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098-1101.
6. Zeng H, Yang K, Cloer C, et al. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature. 2013;499(7459):485-490.
7. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529.
8. Dabney R, Devine R, Sein N, George B New agents in renal cell carcinoma. Target Oncol. 2014;9(3):183-193.
9. Krueger DA. Management of CNS-related disease manifestations in patients with tuberous sclerosis complex. Curr Treat Options Neurol. 2013;15(5):618-633.
10. Eshleman JS, Carlson BL, Mladek AC, et al. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 2002;62(24): 7291-7297.
11. Rao RD, Mladek AC, Lamont JD, et al. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia. 2005;7(10):921-929.
12. Jaboin JJ, Shinohara ET, Moretti L, et al. The role of mTOR inhibition in augmenting radiation induced autophagy. Technol Cancer Res Treat. 2007;6(5):443-447.
13. El Habr EA, Adamopoulos C, Levidou G, et al. The clinical and prognostic significance of activated Akt-mTOR pathway in human astrocytomas. Neurol Res Int. 2012;2012:454957.
14. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J Clin Oncol. 2005; 23(23):5294-5304.
15. Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43(9):1210-1217.
16. Toyohara J, Waki A, Takamatsu S, et al. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002; 29(3):281-287.
17. Waldherr C, Mellinghoff IK, Tran C, et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med. 2005; 46(1):114-120.
18. Grosu AL, Weber WA. PET for radiation treatment planning of brain tumours. Radiother Oncol. 2010;96(3):325-327.
19. Hong IK, Kim JH, Ra YS, et al. Diagnostic usefulness of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography in recurrent brain tumor. J Comput Assist Tomogr. 2011;35(6): 679-684.
20. Rueger MA, Ameli M, Li H, et al. [18F]FLT PET for non-invasive monitoring of early response to gene therapy in experimental gliomas. Mol Imaging Biol. 2011;13(3):547-557.
21. Schwarzenberg J, Czernin J, Cloughesy TF, et al. 3′-Deoxy-3′-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012;53(1):29-36.
22. Aide N, Kinross K, Cullinane C, et al. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med. 2010;51(10):1559-1564.
23. Sarkaria JN, Galanis E, Wu W, et al. North Central Cancer Treatment Group phase I trial N057 K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011;81(2):468-475.
24. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
25. Barwick T, Bencherif B, Mountz JM, et al. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun. 2009;30(12):908-917.
26. Gruber Filbin M, Dabral SK, Pazyra-Murphy MF, et al. Coordinate activation of Shh and PI3 K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med. 2013; 19(11):1518-1523.
27. Tee AR, Manning BD, Roux PP, et al. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003;13(15):1259-1268.
28. Choo AY, Blenis J. TORgeting oncogene addiction for cancer therapy. Cancer Cell. 2006;9(2):77-79.
29. Banerjee S, Crouse NR, Emnett RJ, et al. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proc Natl Acad Sci U S A. 2011;108(38):15996-16001.
30. Franz DN, Weiss BD. Molecular therapies for tuberous sclerosis and neurofibromatosis. Curr Neurol Neurosci Rep. 2012;12(3): 294-301.
31. McCubrey JA, Steelman LS, Chappell WH, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 2012;3(9): 954-987.
32. Franz DN. Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biologics. 2013;7: 211-221.
33. Brown PD, Krishnan S, Sarkaria JN, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group study N0177. J Clin Oncol. 2008;26(34): 5603-5609.
34. Mason WP, Macneil M, Kavan P, et al. A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study. Invest New Drugs. 2012;30(6):2344-2351.
35. Chan JA, Blaszkowsky L, Stuart K, et al. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer. 2013; 119(17):3212-3218.
36. Dronca RS, Allred JB, Perez DG, et al. Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol. 2014;37(4):369-376.
37. Bauknecht HC, Romano VC, Rogalla P, et al. Intra- and interobserver variability of linear and volumetric measurements of brain metastases using contrast-enhanced magnetic resonance imaging. Invest Radiol. 2010;45(1):49-56.
38. Provenzale JM, Mancini MC. Assessment of intra-observer variability in measurement of high-grade brain tumors. J Neurooncol. 2012;108(3):477-483.
39. O'Reilly T, McSheehy PM, Kawai R, et al. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol. 2010; 65(4):625-639.
40. Tanaka K, Sasayama T, Mizukawa K, et al. Specific mTOR inhibitor rapamycin enhances cytotoxicity induced by alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) in human U251 malignant glioma cells. J Neurooncol. 2007;84(3):233-244.
41. Chinnaiyan P, Won M, Wen PY, et al. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2013;86(5):880-884.
42. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256-4265.
43. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523.
44. Piccart-Gebhart M, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2. Ninth European Breast Cancer Conference. Glasgow, Scotland, 2014.
45. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009;7(2):e38.
46. Meric-Bernstam F, Akcakanat A, Chen H, et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012;18(6): 1777-1789.
47. Yao JC, Phan AT, Jehl V, et al. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res. 2013; 73(5):1449-1453.
48. Yang L, Clarke MJ, Carlson BL, et al. PTEN loss does not predict for response to RAD001 (everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res. 2008;14(12):3993-4001.
49. Janku F, Broaddus R, Bakkar R, et al. PTEN assessment and PI3K/mTOR inhibitors: importance of simultaneous assessment of MAPK pathway aberrations. ASCO Annual Meeting. Chicago, IL, 2012.
50. Hortobagyi G, Piccart-Gebhart M, Rugo H, et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2. ASCO Annual Meeting. Chicago, IL, 2013.